Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 31, 2023 12:00 ET | Source: PolyPid Ltd.

PolyPid Announces Closing of Underwritten Public Offering, Including Full Exercise of Overallotment Option, and Concurrent Private Placement with $11.4 Million in Aggregate Gross Proceeds

Company Also Restructures Existing Kreos Loan, Deferring Over $3 Million of Repayment PETACH TIKVA, Israel, March 31, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the...
March 29, 2023 07:59 ET | Source: PolyPid Ltd.

PolyPid Announces Pricing of $6.2 Million Underwritten Public Offering of Ordinary Shares and Concurrent $4.4 Million Private Placement of Pre-Funded Warrants

PETACH TIKVA, Israel, March 29, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, announced...
March 28, 2023 16:05 ET | Source: PolyPid Ltd.

PolyPid Announces Proposed Underwritten Public Offering of Ordinary Shares

PETACH TIKVA, Israel, March 28, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, announced...
March 07, 2023 08:00 ET | Source: PolyPid Ltd.

PolyPid to Present at the Barclays Global Healthcare Conference

PETACH TIKVA, Israel, March 07, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today...
February 08, 2023 07:00 ET | Source: PolyPid Ltd.

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results

Following Positive Communication with the FDA, Regulatory Pathway Clarified for D-PLEX100 for Prevention of Abdominal Colorectal Surgical Site Infections Company Expects to Resume Patient...
January 31, 2023 07:00 ET | Source: PolyPid Ltd.

PolyPid to Report Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights on February 8, 2023

PETACH TIKVA, Israel, Jan. 31, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today...
January 24, 2023 07:00 ET | Source: PolyPid Ltd.

PolyPid Provides Positive Regulatory Update for D-PLEX₁₀₀ for the Prevention of Surgical Site Infections in Abdominal Colorectal Surgery

• Regulatory Pathway for a Potential NDA Submission Clarified Following Recent Interactions with the FDA • FDA Acknowledged that SHIELD I Pre-specified Subgroup Results May Provide Supportive...
January 03, 2023 07:00 ET | Source: PolyPid Ltd.

PolyPid Announces Publication in the American Journal of Surgery of Phase 2 Clinical Trial Post-hoc Analysis for D-PLEX₁₀₀ in the Prevention of Surgical Site Infections in Abdominal Surgery

D-PLEX100 Achieved in Phase 2 Trial Significant Reduction in SSIs in Patients with Multiple Preoperative Risk Factors Versus Standard of Care Results Consistent with SHIELD I Phase 3 Post-hoc...
December 12, 2022 07:00 ET | Source: PolyPid Ltd.

PolyPid Announces Scheduling of Type D Meeting with U.S. FDA to Discuss SHIELD I Phase 3 Results and Regulatory Pathway for D-PLEX₁₀₀ for the Prevention of Surgical Site Infections in Abdominal Colorectal Surgery

Meeting Scheduled for January 2023 PolyPid Recently Provided FDA with Currently Available Data from Completed SHIELD I Phase 3 Study in Advance of Meeting PETACH TIKVA, Israel, Dec. 12,...
December 09, 2022 16:01 ET | Source: PolyPid Ltd.

PolyPid Announces Receipt of Nasdaq Minimum Bid Price Notification

PETACH TIKVA, Israel, Dec. 09, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today...